Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 7/20 | 0.44 |
| ▸ | NOS1 | P29475 | 6/20 | 0.44 |
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornithine SCHEMBL3000505 | 1.00 | GSR (0.64) | GSRCPB2NOS2NOS1NOS3 | |
| Lysine SCHEMBL7037399 | 0.94 | GSR (0.74) | GSRCPB2NOS2NOS1NOS3 | |
| Lysine SCHEMBL7040784 | 0.94 | GSR (0.74) | GSRCPB2NOS2NOS1NOS3 | |
| Ornithine SCHEMBL6757036 | 0.92 | GSR (0.64) | GSRCPB2NOS2NOS1NOS3 | |
| Ornithine SCHEMBL3443860 | 0.86 | GSR (0.78) | GSRNOS2NOS1NOS3CYP2C19 | |
| Ornithine Aketoglutarate SCHEMBL28452040 | 0.86 | GSR (0.78) | GSRNOS2NOS1NOS3CYP2C19 | |
| D-Ornithine SCHEMBL43724 | 0.85 | — | — | |
| Ornithine SCHEMBL624782 | 0.85 | GSR (0.86) | GSRCPB2NOS2NOS1NOS3 | |
| Ornithine Aketoglutarate SCHEMBL1326163 | 0.85 | GSR (0.86) | GSRCPB2NOS2NOS1NOS3 | |
| D-Ornithine SCHEMBL1537220 | 0.85 | GSR (0.86) | GSRCPB2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246470-A1 | COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLS | UCL BUSINESS LTD (GB) | 2021-08-12 | — | — | US | claimed |
| EP-3781676-A1 | COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLS | UCL BUSINESS LTD (GB) | 2021-02-24 | — | — | EP | claimed |
| EP-4351649-A1 | NUCLEIC ACID VECTOR COMPOSITIONS | Sisaf Ltd (GB) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351510-A1 | COMPOSITIONS COMPRISING DOPED SILICON PARTICLES, AND RELATED METHODS | Sisaf Ltd (GB) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351532-A1 | PROTECTION OF BIOLOGICAL SPECIES FROM DEGRADATION | Sisaf Ltd (GB) | 2024-04-17 | — | — | EP | disclosed |
| CN-117715629-A | Protecting biological products from degradation | SISAF有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023233159-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | SISAF LTD (GB) | 2023-12-07 | — | — | WO | disclosed |
| US-11793756-B2 | Anionic nanocomplexes for nucleic acid delivery | UCL BUSINESS PLC (GB) | 2023-10-24 | — | — | US | disclosed |
| EP-3737357-B1 | ANIONIC NANOCOMPLEXES FOR NUCLEIC ACID DELIVERY | UCL BUSINESS PLC (GB) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023002222-A1 | COMPOSITIONS COMPRISING DOPED SILICON PARTICLES, AND RELATED METHODS | SISAF LTD (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002224-A1 | PROTECTION OF BIOLOGICAL SPECIES FROM DEGRADATION | SISAF LTD (GB) | 2023-01-26 | — | — | WO | disclosed |
| EP-3426630-B1 | LIPIDS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | RYBOQUIN COMPANY LTD (GB) | 2020-05-06 | — | — | EP | disclosed |
| US-20190084923-A1 | LIPIDS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | RYBOQUIN COMPANY LTD (GB) | 2019-03-21 | — | — | US | disclosed |
| EP-3426630-A1 | LIPIDS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | Ryboquin Company Ltd (GB) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153779-A1 | LIPIDS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | UCL BUSINESS PLC (GB) | 2017-09-14 | — | — | WO | disclosed |
| US-9399016-B2 | Materials and complexes for the delivery of biologically-active materials to cells | UCL BUSINESS PLC (GB) | 2016-07-26 | — | — | US | disclosed |
| EP-2035566-B1 | MATERIALS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | UNIV LONDON (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-20100184831-A1 | Materials and Complexes for the Delivery of Biologically-Active Materials to Cells | NANOGENICS LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2035566-A2 | MATERIALS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | University College London (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007138324-A2 | MATERIALS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | UNIVERSITY COLLEGE LONDON (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084923-A1 | LIPIDS AND COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | LPAR4, LPAR3, LIPC | GSR 2702/4885CPB2 874/4885NOS2 4117/4885 |
| US-20100184831-A1 | Materials and Complexes for the Delivery of Biologically-Active Materials to Cells | MSR1, LDLR, LNPEP | GSR 2003/4885CPB2 362/4885NOS2 3920/4885 |
| US-20210246470-A1 | COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLS | HNRNPAB, HNRNPA2B1, HNRNPA1 | GSR 3184/4885CPB2 1108/4885NOS2 4852/4885 |
| US-11793756-B2 | Anionic nanocomplexes for nucleic acid delivery | LNPEP, LDLR, APLNR | GSR 2989/4885CPB2 835/4885NOS2 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.